CTOs on the Move

Cullgen

www.cullgen.com

 
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cullgen.com
  • 12671 High Bluff Drive Suite 130
    San Diego, AK USA 92130
  • Phone: 858.284.0115

Executives

Name Title Contact Details

Funding

Cullgen raised $16M on 04/10/2019
Cullgen raised $50M on 02/25/2021

Similar Companies

Muse bio

Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.

SABiosciences Corporation

SABiosciences Corporation is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argene SA

Argene SA is a Massapequa, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Y-mAbs Therapeutics

YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.

Immunomic Therapuetics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.